Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Apr 19, 2023--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2023, after the close of market on Wednesday, May 3, 2023.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/614563599, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 083848. International dial-in numbers are available here: https://www.netroadshow.com/events/global-numbers?confId=48738; please use the same access code above to join the call.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UM Seq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230419005260/en/
CONTACT: Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.comMedia Contact:
Allison Marshall
amarshall@castlebiosciences.com
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL SUPPLIES ONCOLOGY GENERAL HEALTH HEALTH MENTAL HEALTH MEDICAL DEVICES HOSPITALS
SOURCE: Castle Biosciences, Inc.
Copyright Business Wire 2023.
PUB: 04/19/2023 07:00 AM/DISC: 04/19/2023 07:01 AM
http://www.businesswire.com/news/home/20230419005260/en
